Preclinical stroke research gains and gaps

Stroke

Volumn 44, Issue SUPPL. 1, 2013, Pages

  Greenberg, David A ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Ischemia; Neuroprotection; Stroke

Indexed keywords

FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT;

CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ISCHEMIA; NEUROPROTECTION; STROKE;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); RODENTIA; STROKE; UNITED STATES;

EID: 84880255985     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002088     Document Type: Conference Paper

References (11)

1. Final Report of the Stroke Progress Review Group -January 2012. http://www.ninds.nih.gov/find-people/groups/stroke-prg/01-2012-stroke-prg- report.htm.
2. Wang-Fischer Y, Koetzner L. Animal models of ischemic stroke: a historical survey. In Wang-Fischer Y, ed. Manual of Stroke Models in Rats. Boca Raton FL, CRC Press; 2009:5-11.
3. Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci. 1995;16:123-128.
4. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke.1999;30:2752-2758.
5. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478.
6. Macrae IM. Preclinical stroke research -advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol. 2011;164:1062-1078.
7. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
8. Schifilliti D, Grasso G, Conti A, Fodale V. Anaesthetic-related neuroprotection: intravenous or inhalational agents? CNS Drugs. 2010;24:893-907.
9. Buga AM, Vintilescu R, Pop OT, Popa-Wagner A. Brain aging and regeneration after injuries: an organismal approach. Aging Dis. 2011;2:64-79.
10. Roussel S, Pinard E, Seylaz J. Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. Hypertension. 1992;19:40-46.
11. Bômont L, MacKenzie ET. Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats. Neurosci Lett. 1995;197:53-56.